Axsome Therapeutics (AXSM) to Release Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Axsome Therapeutics to post earnings of ($1.36) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported ($1.24) earnings per share for the quarter, topping analysts' consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. The firm had revenue of $87.17 million during the quarter, compared to analyst estimates of $84.53 million. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Axsome Therapeutics Trading Up 2.0 %

AXSM traded up $1.77 on Tuesday, hitting $89.02. 174,292 shares of the company were exchanged, compared to its average volume of 614,330. The company has a debt-to-equity ratio of 1.77, a quick ratio of 2.40 and a current ratio of 2.48. The firm has a fifty day simple moving average of $90.19 and a two-hundred day simple moving average of $83.07. The stock has a market capitalization of $4.23 billion, a PE ratio of -13.63 and a beta of 1.26. Axsome Therapeutics has a 12 month low of $55.02 and a 12 month high of $98.40.

Insiders Place Their Bets

In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the transaction, the director now directly owns 10,002 shares of the company's stock, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mark L. Jacobson sold 47,739 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $84.26, for a total value of $4,022,488.14. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at approximately $487,275.58. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 22.40% of the company's stock.

Wall Street Analysts Forecast Growth

AXSM has been the topic of a number of recent analyst reports. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, October 1st. Bank of America upgraded Axsome Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $95.00 to $106.00 in a research report on Tuesday, August 6th. Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research note on Friday, October 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $107.00 target price on shares of Axsome Therapeutics in a report on Monday, September 16th. Finally, HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research note on Thursday, September 5th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $124.64.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.